Andrew Warner
University of Western Ontario
29 Papers
83 Citations
Andrew Warner is an academic researcher from University of Western Ontario. The author has contributed to research in topics: SABR volatility model & Medicine. The author has an hindex of 10, co-authored 29 publications.
Chat about Author
Papers
Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial.
Anthony C. Nichols,Julie A. Theurer,Eitan Prisman,Nancy Read,Eric Berthelet,Eric Tran,Kevin Fung,John R. de Almeida,Andrew Bayley,David P. Goldstein,Michael P. Hier,Khalil Sultanem,Keith Richardson,Alex Mlynarek,Suren Krishnan,Hien Le,John Yoo,S. Danielle MacNeil,Eric Winquist,J. Alex Hammond,Varagur Venkatesan,Sara Kuruvilla,Andrew Warner,Sylvia Mitchell,Jeff Chen,Martin Corsten,Stephanie Johnson-Obaseki,Libni Eapen,Michael Odell,Christina Parker,Bret Wehrli,Keith Kwan,David A. Palma +32 more
TL;DR: Patients treated with radiotherapy showed superior swallowing-related QOL scores 1 year after treatment, although the difference did not represent a clinically meaningful change, and toxicity patterns differed between the groups.
413
Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis.
Naomi E. Verstegen,J.W.A. Oosterhuis,David A. Palma,G. Rodrigues,Frank J. Lagerwaard,A. van der Elst,R. Mollema,W.F. van Tets,Andrew Warner,J.J.A. Joosten,M.I. Amir,C.J.A. Haasbeek,Egbert F. Smit,Ben J. Slotman,Suresh Senan +14 more
TL;DR: This retrospective analysis found a superior LRC after SABR compared with VATS lobectomy, but OS did not differ, supporting the need to compare both treatments in a randomized, controlled trial.
277
A Phase 1/2 Trial of Brief Androgen Suppression and Stereotactic Radiation Therapy (FASTR) for High-Risk Prostate Cancer
Glenn Bauman,Michelle Ferguson,Michael Lock,Jeff Chen,Belal Ahmad,Varagur Venkatesan,Tracy Sexton,David D'Souza,Andrew Loblaw,Andrew Warner,George Rodrigues +10 more
TL;DR: This novel condensed treatment had higher than anticipated late toxicities and was terminated before phase 2 accrual.
69
Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs
Eva M. Bongers,Angela Botticella,David A. Palma,Cornelis J.A. Haasbeek,Andrew Warner,Wilko F.A.R. Verbakel,Ben J. Slotman,Umberto Ricardi,Suresh Senan +8 more
TL;DR: ContralateralMLD and ITV size are both strong predictors of grade ≥3 RP post treatment, and planning constraints should aim to keep contralateral MLD below 3.6 Gy.
62
Predicting Overall Survival After Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model.
Alexander V. Louie,Alexander V. Louie,Alexander V. Louie,Cornelis J.A. Haasbeek,Sahar Mokhles,George Rodrigues,Kevin L. Stephans,Frank J. Lagerwaard,David A. Palma,Gregory M.M. Videtic,Andrew Warner,Johanna J.M. Takkenberg,Chandana A. Reddy,Alex P.W.M. Maat,Neil M. Woody,Ben J. Slotman,Suresh Senan +16 more
TL;DR: The Amsterdam prognostic model is the first externally validated prognostication tool for OS in ES-NSCLC treated with SABR available to individualize patient decision making.
31